Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator

December 5, 2024 0

Nuvig Therapeutics in the NEWS Nuvig Therapeutics – a privately held biotech company, developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners, with participation from new investors, B Capital, Leaps by …

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the...

The United States FDA Approved Astellas’ product VYLOY in Combination...

U.S. FDA Approves AbbVie’s VYALEV™ for Adults Living with Advanced...

Novo Nordisk Launches New Initiative To Prevent Childhood Obesity In...

The FDA Approved IntraBio Product AQNEURSA As the only treatment...

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet...

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients...

SCG Cell Therapy: FDA Approved IND Application of Product SCG142...

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612...

AstraZeneca: The U.S. FDA Approved IMFINZI in Combination with Carboplatin...

Regeneron: Improved Hearing to Normal Levels in a Child with...

INmune Bio Inc. Update on Two Alzheimer Disease Patients Who...

Cerevel Therapeutics Announces Positive Results for Tavapadon in Phase 3...

Italfarmaco Received FDA Approval for Duvyzat™ for the Treatment of...

Abbott Laboratories Launches a New PROTALITY™ Brand to Maintain the...

Sanofi to Acquire Inhibrx, Inc.

Cognition Therapeutics CEO Issues Letter to Shareholders

For Migraine Patients and People Interested in New Migraine Results,...

Today at 2 PM, Akero Therapeutics Presented at the H.C....

Impacting News

Conferences Announced by Verona Pharma and GRAIL Inc

February 24, 2025 0

Verona Pharma Conference Announcements Verona Pharma (VRNA) announces that senior management will present a company overview …

The European Commission Granted Approval to Gilead Sciences’ Seladelpar in Combination with UDCA for the Treatment of Primary Biliary Cholangitis

February 21, 2025 0

Gilead Sciences On February 20, 2025, Gilead Sciences (GILD) announced that the European Commission (EC) granted …

Boehringer Ingelheim Product Nerandomilast Meets Primary Endpoint in Phase III Study in Progressive Pulmonary Fibrosis

February 10, 2025 0

Boehringer Ingelheim Today, Boehringer Ingelheim, a private Company announced that the FIBRONEER™-ILD trial met its primary …

Vertex Outstanding and Promising News

January 31, 2025 0

Vertex Pharmaceuticals Yesterday, January 30, 2025, Vertex Pharmaceuticals (VRTX) announced FDA approval of journavx™(suzetrigine), a First-in-Class …

The U.S. FDA Approved Daiichi Sankyo and AstraZeneca’s Product ENHERTU® for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

January 29, 2025 0

AstraZeneca FDA Approval On January 27, 2025, Daiichi Sankyo (TSE: 4568) and AstraZeneca (AZN) product ENHERTU® (fam-trastuzumab …

A Reminder: Verastem Oncology Announced FDA Acceptance and Priority Review of the NDA Avutometinib (in Combination with Defactinib) for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

January 6, 2025 0

Verastem Oncology in the NEWS On December 30, 2024, Verastem Oncology (VSTM) announced that the U.S. …

Trick or Trade

Can Cassava Sciences Resurrect When Simufilam is Used to Treat Seizures Related to Rare Neurodevelopmental Disorders Instead of Alzheimer’s Disease?

February 28, 2025 0

Cassava Sciences in the NEWS Cassava Sciences, Inc. (SAVA) announced that it entered into an agreement …

Q & A About Alnylam Pharmaceuticals

February 19, 2025 0

Alnylam Pharmaceuticals Questions & Answers Q: Why has Alnylam Pharmaceuticals’ stock plummeted recently? A: We do …

Soon, Many Treatments for Life-Threatening Diseases Will Become History. Time to Select Biotech Companies With Novel Advanced Technologies and Products

February 18, 2025 0

What About GRAIL Inc? GRAIL Inc (GRAL) is a healthcare company on a mission to detect …

Revisiting Bluebird Bio Inc

December 18, 2024 0

Bluebird Bio Inc For investors who thought that bluebird bio Inc (BLUE) stock price jumped up …

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024 0

InflaRX In March 2024, InflaRx Biopharmaceutical (IFRX) announced that it will pursue two initial immuno-dermatology indications …

Some Stories To Know About Vera and Viking Therapeutics

October 29, 2024 0

Vera Therapeutics and Viking Therapeutics Today, October 29, the market stocks’ prices moved south, including good …

Today’s Highlights

Alnylam Pharmaceuticals Press Release Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

February 25, 2025 0

– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, …

Sanofi Updates on Extraintestinal Pathogenic E. coli Vaccine Phase 3 Clinical Study

February 13, 2025 0

Sanofi A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by …

Our Prohost Small Test and Anavex Life Sciences Earning Report

February 12, 2025 0

Anavex Life Sciences Below Today is the earnings report day for Anavex Life Sciences (AVXL) and …

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

February 7, 2025 0

Eledon Pharmaceuticals The patient was treated in the procedure, conducted at Mass General Transplant Center and …

Supernus Pharmaceuticals Announced FDA Approval of product ONAPGO for the Treatment of Motor Fluctuations in Adults with Advanced Parkinson’s Disease

February 5, 2025 0

Supernus Pharmaceuticals Supernus Pharmaceuticals (SUPN) - a biopharmaceutical company focused on developing products for the treatment …

CHMP Issued Positive Opinion for Subcutaneous RYBREVANT® Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

February 3, 2025 0

Halozyme Therapeutics Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received …

Latest Articlesddd

Can Cassava Sciences Resurrect When Simufilam is Used to Treat Seizures Related to Rare Neurodevelopmental Disorders Instead of Alzheimer’s Disease?

February 28, 2025 0

Cassava Sciences in the NEWS Cassava Sciences, Inc. (SAVA) announced that it entered into an agreement …

Alnylam Pharmaceuticals Press Release Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

February 25, 2025 0

– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, …

Conferences Announced by Verona Pharma and GRAIL Inc

February 24, 2025 0

Verona Pharma Conference Announcements Verona Pharma (VRNA) announces that senior management will present a company overview …

The European Commission Granted Approval to Gilead Sciences’ Seladelpar in Combination with UDCA for the Treatment of Primary Biliary Cholangitis

February 21, 2025 0

Gilead Sciences On February 20, 2025, Gilead Sciences (GILD) announced that the European Commission (EC) granted …

Q & A About Alnylam Pharmaceuticals

February 19, 2025 0

Alnylam Pharmaceuticals Questions & Answers Q: Why has Alnylam Pharmaceuticals’ stock plummeted recently? A: We do …

Soon, Many Treatments for Life-Threatening Diseases Will Become History. Time to Select Biotech Companies With Novel Advanced Technologies and Products

February 18, 2025 0

What About GRAIL Inc? GRAIL Inc (GRAL) is a healthcare company on a mission to detect …

Sanofi Updates on Extraintestinal Pathogenic E. coli Vaccine Phase 3 Clinical Study

February 13, 2025 0

Sanofi A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by …

Our Prohost Small Test and Anavex Life Sciences Earning Report

February 12, 2025 0

Anavex Life Sciences Below Today is the earnings report day for Anavex Life Sciences (AVXL) and …

Boehringer Ingelheim Product Nerandomilast Meets Primary Endpoint in Phase III Study in Progressive Pulmonary Fibrosis

February 10, 2025 0

Boehringer Ingelheim Today, Boehringer Ingelheim, a private Company announced that the FIBRONEER™-ILD trial met its primary …

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

February 7, 2025 0

Eledon Pharmaceuticals The patient was treated in the procedure, conducted at Mass General Transplant Center and …

Supernus Pharmaceuticals Announced FDA Approval of product ONAPGO for the Treatment of Motor Fluctuations in Adults with Advanced Parkinson’s Disease

February 5, 2025 0

Supernus Pharmaceuticals Supernus Pharmaceuticals (SUPN) - a biopharmaceutical company focused on developing products for the treatment …

CHMP Issued Positive Opinion for Subcutaneous RYBREVANT® Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

February 3, 2025 0

Halozyme Therapeutics Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received …

Vertex Outstanding and Promising News

January 31, 2025 0

Vertex Pharmaceuticals Yesterday, January 30, 2025, Vertex Pharmaceuticals (VRTX) announced FDA approval of journavx™(suzetrigine), a First-in-Class …

The U.S. FDA Approved Daiichi Sankyo and AstraZeneca’s Product ENHERTU® for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

January 29, 2025 0

AstraZeneca FDA Approval On January 27, 2025, Daiichi Sankyo (TSE: 4568) and AstraZeneca (AZN) product ENHERTU® (fam-trastuzumab …

Complete Preliminary Week 96 Results from Akero Therapeutics EFX Results

January 27, 2025 0

Akero Therapeutics Full Press Release Following our shortened report earlier today, this posting is from the …

Akero Therapeutics Successful Results

January 27, 2025 0

Akero Therapeutics Waiting to hear the news from Akero Therapeutics in treating NASH, the company reported …

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

January 13, 2025 0

Vera Therapeutics in the Market Today Today, many investors in the biotechnology market caused a selloff …

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors.

January 8, 2025 0

Compugen January 8, 2025, Compugen (CGEN), announced that the first patient was dosed in a Phase …